Niiyama Shiro, Yokouchi Yuki, Fukuda Hidetsugu
Shiro Niiyama, MD, PhD, Department of Dermatology, Toho University Ohashi Medical Center, 2-22-36 Ohashi, Meguro-ku, Tokyo 153-8515 Japan;
Acta Dermatovenerol Croat. 2024 Dec;32(4):212-213.
Vogt-Koyanagi-Harada (VKH) disease is a multisystem autoimmune disorder affecting melanocyte-containing tissues such as the eyes, ears, central nervous system, and skin. A 55-year-old Japanese male presented with an 8-week history of increasing diffuse hair loss. A physical examination revealed diffuse alopecia of the scalp. He lost all body hair, including the eyebrows and eyelashes. All the remaining scalp hair was white, but no vitiligo was present. Laboratory examination found nearly normal values and the HLA profile was DR4. The patient was initially diagnosed with alopecia universalis and received 15 intradermal injections of 1 mg of triamcinolone acetonide to the same region. As a result, although no hair growth was observed, the patient's hair turned black in the area of the local injections (Figure 1, a). We therefore reviewed the patient's medical history again and found that he had developed bilateral uveitis at the age of 20 years and received high-dose intravenous corticosteroid therapy. He also consulted an ophthalmologist at the time, but there were no abnormal findings. Two biopsies were performed in both the white and black hair. Histopathologically, no melanin was detected in the white hair (Figure 1, b), whereas the black hair demonstrated melanin granules in the hair matrix (Figure 1, c). Treatment was started with oral prednisolone at a dose of 30 mg per day, with the dose gradually reduced by 5 mg every 2 weeks. When the treatment was discontinued, a considerable part of the hair had turned black (Figure 1, d). VKH disease typically has three phases. During the first phase, patients may experience headache, muscle weakness, and meningism. Recovery is usually complete, and is followed by the second phase days to weeks later, in which patients may develop uveitis, iridocyclitis, choroiditis, and dysacousia. The third phase begins weeks to months later as the uveitis improves. The third phase is the convalescent phase, and is characterized by alopecia, poliosis, and vitiligo; usually occurring in that order. These dermatologic manifestations have been reported in about 50% of patients by two months after disease onset (1). Poliosis is either patchy or diffuse and occurs in up to 90% of the patients (2). In our case, the amount of white hair began to increase 20 years after the onset of uveitis, and all the hair turned white over the course of a few years. Such a late onset of poliosis has not been reported so far, and steroid treatment resulted in repigmentation even approximately 15 years after all the hair turned white. Reversal of poliosis and vitiligo in the VKH setting has been reported in 6 of 22 (27%) patients (3). All patients with reversal of poliosis and vitiligo had no intraocular inflammation. The reversal may represent a good prognostic sign. Our patient also experienced no recurrence of ocular symptoms. Alopecia can be observed in 50%-70% of cases of VKH disease and occurs a few weeks to a few months after onset of ocular or meningeal symptoms (4). It presents as diffuse, although it may be patchy. Alopecia usually heals after a variable period of time with steroid or immunosuppressive therapy. Microscopically, alopecia in VKH disease shows a peribulbar mononuclear infiltrate with increased telogen/catagen/anagen follicles (2). So far, no reports have compared the histopathological findings of white and black hair in the same patients. No inflammatory infiltrate was present in our case. The reason for this may be the chronic phase of the disease. Our patient developed alopecia 35 years after the onset of uveitis, and such a late onset of alopecia as well as poliosis has not been reported so far. Unfortunately, we have observed no growth of scalp hair. The patient continues to attend follow-up, with special attention to the potential onset of vitiligo.
伏格特-小柳-原田(VKH)病是一种多系统自身免疫性疾病,可累及含黑素细胞的组织,如眼睛、耳朵、中枢神经系统和皮肤。一名55岁的日本男性,有8周弥漫性脱发加重的病史。体格检查发现头皮弥漫性脱发。他全身毛发脱落,包括眉毛和睫毛。剩余的头皮毛发均为白色,但无白癜风表现。实验室检查结果基本正常,人类白细胞抗原(HLA)分型为DR4。患者最初被诊断为全秃,并在同一部位接受了15次皮内注射1mg曲安奈德。结果,虽然未观察到毛发再生,但患者局部注射区域的毛发变黑(图1,a)。因此,我们再次回顾了患者的病史,发现他20岁时曾患双侧葡萄膜炎,并接受了大剂量静脉注射皮质类固醇治疗。当时他也咨询过眼科医生,但未发现异常。对白色和黑色毛发均进行了两次活检。组织病理学检查显示,白色毛发中未检测到黑色素(图1,b),而黑色毛发的毛基质中有黑色素颗粒(图1,c)。开始口服泼尼松龙治疗,剂量为每日30mg,每2周逐渐减少5mg。停药时,相当一部分毛发已变黑(图1,d)。VKH病通常有三个阶段。在第一阶段,患者可能会出现头痛、肌肉无力和脑膜刺激征。通常可完全恢复,数天至数周后进入第二阶段,患者可能会出现葡萄膜炎、虹膜睫状体炎、脉络膜炎和听力障碍。第三阶段在葡萄膜炎改善数周数月后开始。第三阶段为恢复期,其特征为脱发、白发和白癜风;通常按此顺序出现。据报道,约50%的患者在疾病发作后两个月内出现这些皮肤表现(1)。白发可为斑片状或弥漫性,高达90%的患者会出现(2)。在我们的病例中,葡萄膜炎发作20年后白发数量开始增加,几年内所有毛发都变白了。如此晚发的白发此前尚未见报道,而且即使在所有毛发变白约15年后,类固醇治疗仍导致色素再生。在22例患者中有6例(27%)报道了VKH病中白发和白癜风的逆转(3)。所有白发和白癜风逆转的患者均无眼内炎症。这种逆转可能是一个良好的预后标志。我们的患者也未出现眼部症状复发。50%-70%的VKH病患者会出现脱发,发生在眼部或脑膜症状发作后的几周至几个月内(4)。表现为弥漫性,也可能为斑片状。脱发通常在接受类固醇或免疫抑制治疗后的一段时间内愈合。显微镜下,VKH病中的脱发表现为毛囊周围单核细胞浸润,休止期/退行期/生长期毛囊增多(2)。到目前为止,尚无关于同一患者白色和黑色毛发组织病理学检查结果比较的报道。我们的病例中未出现炎症浸润。原因可能是疾病处于慢性期。我们的患者在葡萄膜炎发作35年后出现脱发,如此晚发的脱发和白发此前尚未见报道。不幸的是,我们未观察到头皮毛发再生。患者继续接受随访,特别关注白癜风的潜在发作。